recombinant human Hsp110-gp100 chaperone complex vaccine / National Cancer Institute, Roswell Park Comprehensive Cancer Center - LARVOL DELTA

SRA inhibition improves antitumor potency of antigen-targeted chaperone vaccine. (PubMed, Front Immunol) - "We show that short hairpin RNA-mediated SRA silencing significantly enhances the immunogenicity of DCs that have captured chaperone vaccines designed to target melanoma (i.e., hsp110-gp100) and breast cancer (i.e., hsp110-HER/Neu-ICD)...Targeting SRA with this chitosan-siRNA regimen combined with the chaperone vaccine also leads to reprogramming of the tumor environment, indicated by elevation of the cytokine genes (i.e., ifng, il12) known to skew Th1-like cellular immunity and increased tumor infiltration by IFN-γCD8 CTLs as well as IL-12CD11c DCs. Given the promising antitumor activity and safety profile of chaperone vaccine in cancer patients, further optimization of the chitosan-siRNA formulation to potentially broaden the immunotherapeutic benefits of chaperone vaccine is warranted."

IO biomarker • Journal • Breast Cancer • Melanoma • Oncology • Solid Tumor • CD8 • HSPH1 • IFNG • IL12A • ITGAX

Recombinant human Hsp110-gp100 chaperone complex vaccine is nontoxic and induces response in advanced stage melanoma patients. (PubMed, Melanoma Res) - "A fully recombinant human Hsp110-gp100 chaperone complex vaccine had minimal toxicity, measurable tumor responses at lower doses and produced peripheral CD8+ T cell activation in patients with advanced, pretreated melanoma. Combination with currently available immunotherapies may augment clinical responses."

Journal • Dermatology • Immune Modulation • Inflammation • Melanoma • Oncology • Solid Tumor • CD8 • CTLA4 • HSPH1 • IFNG • PD-1

[VIRTUAL] Recombinant Human hsp110-gp100 Chaperone Complex Vaccine is Non-toxic and Induces Response in Advanced Stage Melanoma Patients (SSO 2020) - "A fully recombinant human hsp110-gp100 chaperone complex vaccine had minimal toxicity, measurable tumor responses at lower doses, and produced peripheral CD8+ T-cell activation in patients with advanced, pretreated melanoma. Future directions include combination with currently available immunotherapies and multiantigen vaccine development."

Clinical • IO Biomarker • Dermatology • Melanoma • Oncology • Solid Tumor • CD8 • CTLA4 • HAVCR2 • LAG3 • PD-1

Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma (clinicaltrials.gov) - P1; N=10; Terminated; Sponsor: Roswell Park Cancer Institute; Suspended ➔ Terminated; Study was Suspended since 2018; PI decided to terminate.

Clinical • Trial termination • Melanoma • Oncology • Solid Tumor • BRAF

Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Roswell Park Cancer Institute; Trial primary completion date: Nov 2014 ->Jun 2015

Trial primary completion date • Biosimilar • Melanoma • Oncology

Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma (clinicaltrials.gov) - P1; N=9; Suspended; Sponsor: Roswell Park Cancer Institute; Trial completion date: Dec 2019 ➔ Jun 2020

Clinical • Trial completion date • BRAF

Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma (clinicaltrials.gov) - P1; N=9; Suspended; Sponsor: Roswell Park Cancer Institute; Active, not recruiting ➔ Suspended

Clinical • Trial suspension

Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma (clinicaltrials.gov) - P1; N=9; Active, not recruiting; Sponsor: Roswell Park Cancer Institute; Recruiting ➔ Active, not recruiting; N=20 ➔ 9; Trial primary completion date: Feb 2019 ➔ Jun 2018

Clinical • Enrollment change • Enrollment closed • Trial primary completion date